Efficacy and safety of vedolizumab in Crohn’s disease in patients from Asian countries in the GEMINI 2 study

BACKGROUND/AIMS: The efficacy and safety of vedolizumab in moderate-to-severely active Crohn’s disease (CD) were demonstrated in the GEMINI 2 study (NCT00783692). This post-hoc exploratory analysis aimed to assess the efficacy and safety of vedolizumab in the subgroup of patients from Asian countrie...

Descripción completa

Detalles Bibliográficos
Autores principales: Banerjee, Rupa, Chuah, Sai Wei, Hilmi, Ida Normiha, Wu, Deng-Chyang, Yang, Suk-Kyun, Demuth, Dirk, Lindner, Dirk, Adsul, Shashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association for the Study of Intestinal Diseases 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873405/
https://www.ncbi.nlm.nih.gov/pubmed/33378612
http://dx.doi.org/10.5217/ir.2019.09160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873405/
https://www.ncbi.nlm.nih.gov/pubmed/33378612
http://dx.doi.org/10.5217/ir.2019.09160

Ejemplares similares